First International Quality Control Programme for Laboratories Measuring Antimicrobial Drugs to Support Dose Individualization in Critically Ill Patients

Overview

Journal J Antimicrob Chemother

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2020 Oct 23

PMID 33094803

Citations 4

Authors

E Wallenburg

R J Bruggemann

K Asouit

M Teulen

A F J de Haan

E J F Franssen

R E Aarnoutse

Affiliations

Soon will be listed here.

Abstract

Objectives: International quality control (proficiency testing) programmes are instituted to safeguard the analytical performance of laboratories and to aid these laboratories in identifying sources of error in their analytical methods. We describe the first international quality control programme for antimicrobial agents that are frequently used in critically ill patients.

Methods: Spiked plasma samples with ceftazidime, ciprofloxacin, flucloxacillin, piperacillin, sulfamethoxazole, N-acetyl sulfamethoxazole and trimethoprim were shipped to 22 laboratories from eight different countries. Acceptable accuracy by the performing laboratory was defined if measurements were within 80%-120% limits of the true weighed-in concentrations.

Results: A total of 81% of the measurements (ranging between 56% and 100%, dependent on drug) were within the 80%-120% limits of the true weighed-in concentrations.

Conclusions: We found a relatively good performance of the participating laboratories in measuring eight different antimicrobial drugs. Nevertheless, some of the antimicrobial drugs were not measured properly as up to 44% of the measurements was inaccurate depending on the drug. Our results emphasize the need for and utility of an ongoing quality control programme.

Citing Articles

Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations.

Stemkens R, Mouhdad C, Franssen E, Touw D, Alffenaar J, Te Brake L J Antimicrob Chemother. 2024; 79(6):1346-1352.

PMID: 38581098 PMC: 11144482. DOI: 10.1093/jac/dkae105.

Influence of ultrafiltration conditions on the measurement of unbound drug concentrations: flucloxacillin as an example.

Jager N, Van Ewijk-Beneken Kolmer E, Aarnoutse R, Te Brake L J Antimicrob Chemother. 2024; 79(5):1187-1190.

PMID: 38569058 PMC: 11062936. DOI: 10.1093/jac/dkae092.

Development and validation of an UPLC-MS/MS assay for the simultaneous quantification of seven commonly used antibiotics in human plasma and its application in therapeutic drug monitoring.

Mekking X, Velthoven-Graafland K, Teulen M, Bruggemann R, Te Brake L, Jager N J Antimicrob Chemother. 2024; 79(4):883-890.

PMID: 38416407 PMC: 10984926. DOI: 10.1093/jac/dkae047.

Meropenem Stability in Human Plasma at -20 °C: Detailed Assessment of Degradation.

Gijsen M, Filtjens B, Annaert P, Armoudjian Y, Debaveye Y, Wauters J Antibiotics (Basel). 2021; 10(4).

PMID: 33923550 PMC: 8072937. DOI: 10.3390/antibiotics10040449.

References

Roberts J, Abdul-Aziz M, Lipman J, Mouton J, Vinks A, Felton T . Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014; 14(6):498-509. PMC: 4181663. DOI: 10.1016/S1473-3099(14)70036-2. View

Wilkes S, van Berlo I, Ten Oever J, Jansman F, Ter Heine R . Population pharmacokinetic modelling of total and unbound flucloxacillin in non-critically ill patients to devise a rational continuous dosing regimen. Int J Antimicrob Agents. 2018; 53(3):310-317. DOI: 10.1016/j.ijantimicag.2018.11.018. View

Droste J, Aarnoutse R, Koopmans P, Hekster Y, Burger D . Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003; 32(3):287-91. DOI: 10.1097/00126334-200303010-00007. View

Abdul-Aziz M, Alffenaar J, Bassetti M, Bracht H, Dimopoulos G, Marriott D . Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020; 46(6):1127-1153. PMC: 7223855. DOI: 10.1007/s00134-020-06050-1. View

Gieling E, Wallenburg E, Frenzel T, de Lange D, Schouten J, Ten Oever J . Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. Clin Pharmacol Ther. 2020; 108(4):770-774. PMC: 7540326. DOI: 10.1002/cpt.1855. View

Ventola C . The antibiotic resistance crisis: part 1: causes and threats. P T. 2015; 40(4):277-83. PMC: 4378521. View

Autmizguine J, Melloni C, Hornik C, Dallefeld S, Harper B, Yogev R . Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children. Antimicrob Agents Chemother. 2017; 62(1). PMC: 5740321. DOI: 10.1128/AAC.01813-17. View

Bruggemann R, Touw D, Aarnoutse R, Verweij P, Burger D . International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother. 2008; 53(1):303-5. PMC: 2612190. DOI: 10.1128/AAC.00901-08. View

Alobaid A, Wallis S, Jarrett P, Starr T, Stuart J, Lassig-Smith M . Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Antimicrob Agents Chemother. 2017; 61(3). PMC: 5328553. DOI: 10.1128/AAC.01276-16. View

10.

Brown G . Cotrimoxazole - optimal dosing in the critically ill. Ann Intensive Care. 2014; 4:13. PMC: 4031607. DOI: 10.1186/2110-5820-4-13. View

11.

Carlier M, Athanasopoulos A, Borrey D, Colin P, Cotton F, Denooz R . Proficiency Testing for Meropenem and Piperacillin Therapeutic Drug Monitoring: Preliminary Results From the Belgian Society on Infectiology and Clinical Microbiology Pharmacokinetic-Pharmacodynamic Working Group. Ther Drug Monit. 2017; 40(1):156-158. DOI: 10.1097/FTD.0000000000000467. View

12.

Konig C, Braune S, Roberts J, Nierhaus A, Steinmetz O, Baehr M . Population pharmacokinetics and dosing simulations of ceftazidime in critically ill patients receiving sustained low-efficiency dialysis. J Antimicrob Chemother. 2017; 72(5):1433-1440. DOI: 10.1093/jac/dkw592. View

13.

Wong G, Brinkman A, Benefield R, Carlier M, De Waele J, El Helali N . An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother. 2014; 69(5):1416-23. DOI: 10.1093/jac/dkt523. View

14.

Aarnoutse R, Sturkenboom M, Robijns K, Harteveld A, Greijdanus B, Uges D . An interlaboratory quality control programme for the measurement of tuberculosis drugs. Eur Respir J. 2015; 46(1):268-71. DOI: 10.1183/09031936.00177014. View

15.

Matzke G, Aronoff G, Atkinson Jr A, Bennett W, Decker B, Eckardt K . Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80(11):1122-37. DOI: 10.1038/ki.2011.322. View

16.

Burger D, Teulen M, Eerland J, Harteveld A, Aarnoutse R, Touw D . The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program. Ther Drug Monit. 2011; 33(2):239-43. DOI: 10.1097/FTD.0b013e31820fa528. View

17.

Lempers V, Alffenaar J, Touw D, Burger D, Uges D, Aarnoutse R . Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations. J Antimicrob Chemother. 2014; 69(11):2988-94. DOI: 10.1093/jac/dku242. View